Curis Inc (CRIS)
14.94
-1.01
(-6.33%)
USD |
NASDAQ |
Apr 18, 16:00
15.00
+0.06
(+0.40%)
Pre-Market: 20:00
Curis Cash from Financing (TTM): 7.58M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 7.58M |
September 30, 2023 | 8.31M |
June 30, 2023 | 0.416M |
March 31, 2023 | 0.509M |
December 31, 2022 | 0.867M |
September 30, 2022 | 0.943M |
June 30, 2022 | -4.675M |
March 31, 2022 | -4.491M |
December 31, 2021 | -4.172M |
September 30, 2021 | 162.38M |
June 30, 2021 | 169.16M |
March 31, 2021 | 186.21M |
December 31, 2020 | 188.81M |
September 30, 2020 | 22.51M |
June 30, 2020 | 16.08M |
March 31, 2020 | -1.215M |
December 31, 2019 | 23.27M |
September 30, 2019 | 22.69M |
June 30, 2019 | 21.94M |
March 31, 2019 | 21.62M |
December 31, 2018 | -5.961M |
September 30, 2018 | -5.795M |
June 30, 2018 | 30.27M |
March 31, 2018 | 30.91M |
December 31, 2017 | 64.24M |
Date | Value |
---|---|
September 30, 2017 | 66.40M |
June 30, 2017 | 31.08M |
March 31, 2017 | 31.26M |
December 31, 2016 | -1.366M |
September 30, 2016 | -2.424M |
June 30, 2016 | -2.917M |
March 31, 2016 | -3.517M |
December 31, 2015 | 61.66M |
September 30, 2015 | 61.28M |
June 30, 2015 | 61.58M |
March 31, 2015 | 62.57M |
December 31, 2014 | -1.304M |
September 30, 2014 | 6.697M |
June 30, 2014 | 17.33M |
March 31, 2014 | 20.15M |
December 31, 2013 | 20.00M |
September 30, 2013 | 42.76M |
June 30, 2013 | 34.20M |
March 31, 2013 | 32.58M |
December 31, 2012 | 35.82M |
September 30, 2012 | 6.410M |
June 30, 2012 | 5.335M |
March 31, 2012 | 4.755M |
December 31, 2011 | 2.081M |
September 30, 2011 | 1.653M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.675M
Minimum
Jun 2022
188.81M
Maximum
Dec 2020
43.01M
Average
8.31M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Kura Oncology Inc | 94.78M |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Armata Pharmaceuticals Inc | 53.99M |